logowsbdaily | Thu, 21 Oct 2021 07:34:40 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Citius Pharmaceuticals, Inc.
(CTXR)

Citius Pharmaceuticals, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction... Read More

Summary & Charts

Price$ 2.03-0.08 (-3.8%)
Day's Range$ 2.03 - 2.11 
Previous Close$ 2.11
Market Cap$ 228.99M USD
Short Interest %9.01 %As of Wed, 31 Mar 2021
Float122.39M
Outstanding134.7M
ExchangeNasdaqGS
IndustryBiotechnology
SectorHealthcare
Volume1.77M
Avg. Volume (20 day)1.90M
Rel. Volume (20 day)0.93
Rel. Volume (3 month)0.67
RatingB+Buy
DCFN/AStrong Buy
Debt/Equity6.78 %Neutral
ROE-27.55 %Neutral
ROA-17.46 %Neutral
P/E-12.53 %Strong Sell
P/B2.03 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Oct 20, 2021$ 2.10$ 2.11$ 2.03$ 2.03-0.081,767,1850.930.678
Oct 19, 2021$ 2.11$ 2.15$ 2.10$ 2.11+0.021,135,9120.580.424
Oct 18, 2021$ 2.08$ 2.16$ 2.07$ 2.091,891,9340.950.699
Oct 15, 2021$ 2.20$ 2.25$ 2.09$ 2.09-0.112,216,0451.060.766
Oct 14, 2021$ 2.04$ 2.21$ 2.02$ 2.20+0.164,023,7861.931.318
Oct 13, 2021$ 2.01$ 2.13$ 1.98$ 2.04+0.033,457,5601.761.019
Oct 12, 2021$ 2.00$ 2.03$ 2.00$ 2.01-0.03851,9940.450.196
Oct 11, 2021$ 2.04$ 2.06$ 2.00$ 2.041,150,1180.570.25
Oct 08, 2021$ 2.07$ 2.09$ 2.02$ 2.04-0.061,368,1710.660.273
Oct 07, 2021$ 2.04$ 2.11$ 2.03$ 2.10+0.071,874,1590.860.366
Oct 06, 2021$ 2.02$ 2.05$ 1.98$ 2.03-0.011,307,3720.580.225
Oct 05, 2021$ 1.99$ 2.07$ 1.97$ 2.04+0.091,764,3800.750.294
Oct 04, 2021$ 2.02$ 2.03$ 1.95$ 1.95-0.082,211,5670.860.374
Oct 01, 2021$ 2.02$ 2.07$ 1.98$ 2.031,885,0050.730.315
Sep 30, 2021$ 2.02$ 2.08$ 2.01$ 2.03+0.031,346,2690.500.225
Sep 29, 2021$ 2.10$ 2.11$ 2.00$ 2.00-0.081,758,0620.620.281
Sep 28, 2021$ 2.11$ 2.14$ 2.07$ 2.08-0.061,834,6600.630.291
Sep 27, 2021$ 2.08$ 2.17$ 2.07$ 2.14+0.051,988,0420.640.316
Sep 24, 2021$ 2.15$ 2.20$ 2.09$ 2.09-0.062,468,4980.760.382
Sep 23, 2021$ 2.16$ 2.17$ 2.11$ 2.15+0.021,772,6880.540.27

News

The latest news about Citius Pharmaceuticals, Inc. (CTXR).

PennyStocks | 2021-10-17 17:00:00
Which penny stocks are on your watchlist for this coming week? The post Top Penny Stocks to Add to Your Watchlist This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PRNewsWire | 2021-10-13 11:38:00
CRANFORD, N.J., Oct. 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m.
PRNewsWire | 2021-10-06 10:40:00
CRANFORD, N.J., Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
PRNewsWire | 2021-10-01 08:30:00
CRANFORD, N.J., Oct. 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University , Philadelphia, PA, which renamed the main building housing the College of Liberal Arts (CLA) to Leonard and Helena Mazur Hall in recognition of the Mazur's longstanding commitment to Temple University's students and alumni.
PRNewsWire | 2021-09-14 10:06:00
CRANFORD, N.J., Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.
PRNewsWire | 2021-09-08 09:15:00
CRANFORD, N.J., Sept. 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C.
PennyStocks | 2021-08-31 13:24:27
With September only a day away, which penny stocks are on your buy list? The post Best Penny Stocks For Your Buy List in September?

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-08-12BMO-0.05-0.05--------
2021-05-13BMO-0.07-0.0442.86%------
2021-02-11BMO0.16-0.15-193.75%------
2020-08-14BMO-0.1-0.119.99%------
2020-05-14BMO-0.1-0.1330%------
2020-02-13BMO-0.14-0.157.14%------
2019-12-16BMO-0.14-0.1614.28%------
2019-08-14BMO------------

Due Diligences

These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.

$CTXR: 6 year trial and 8 year trial finishing at the same time (roughly)

I weren't get in to Ctxr as most are aware of citrus pharmaceutical, if not then head to ctxr sub reddit for dd. I want to discuss the possibility of getting them tendies on a double catalyst phase 3 trials that are finally ending after 6 years (mino lok) and 8 years (E7777) I think we are going t... Read More

69 comments | 126 votes
Biotech Stocks To Watch This Week (12) - $RSLS $LGVN $CTXR $XCUR

Last week's post seems to have been well received. Here's the TLDR version with dates so ya'll can take a look. Let me know if you find others with important dates this week: **$SNGX - 10/18** This week is all about the HyBryte platform. An abstract was selected and accepted for display and presen... Read More

Top Discussions

These are the top discussions over the last 24-hours that mention the CTXR stock ticker symbol.

Daily Discussion Thread

Discuss your picks and ideas below. This is also a great place for gain/loss pics. Keep things civil....

Any opinions on WTRH?

The company seems fairly solid IMO. It had a big run on friday, and announced a partnership with Olo this morning. PT is $5, but talk of $8 has been everywhere....


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Fri, 30 Jul 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.